<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01448655</url>
  </required_header>
  <id_info>
    <org_study_id>ISC-4.1.5</org_study_id>
    <secondary_id>2010-018682-31</secondary_id>
    <nct_id>NCT01448655</nct_id>
  </id_info>
  <brief_title>Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV)</brief_title>
  <official_title>Prospective Epidemiological Study to Expand Knowledge on Efficacy and Safety of a Routine Post-operative Supportive Therapy With the Mistletoe Extract Iscador® Qu Within Oncological Treatment of Colorectal Cancer Stages UICC II-IV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IFAG AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hiscia Society for Cancer Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IFAG Basel AG (CRO), both Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IFAG AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and safety of a supportive treatment with European mistletoe extract Iscador® Qu
      (&quot;quercus&quot;, i.e. from oak tree) in patients with colorectal cancer (Union for International
      Cancer Control, UICC stages II-IV), in addition to post-operative conventional oncological
      therapy (radio-, chemo-, targeted therapy) as compared to a parallel group with conventional
      therapy only.

      Primary Endpoints: Reduction of adverse effects of conventional therapy; reduction of therapy
      or disease induced symptoms (both are quality of life parameters and evaluated after 1 year);
      prolongation of disease free and/or overall survival (DFS, OS) after 5 years.

      Prospective observational confirmation study of previous retrospective cohort study.

      As this is a non-interventional cohort study, all therapies and measurements are performed on
      directive by the treating physician and/or request by the patient only.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      see summary
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival time (DFS).</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with at least one therapy or disease induced symptom (surrogate parameter for quality of life)</measure>
    <time_frame>1 year</time_frame>
    <description>As key symptom, the fatigue syndrome will be evaluated separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean values of Karnofsky performance status, Eastern Cooperative Oncology Group (ECOG) score</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interim analysis on overall survival time (OS) in UICC stage IV patients</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Iscador® Qu (number of patients with systemic or local adverse events (AE) to Iscador® Qu)</measure>
    <time_frame>5 years</time_frame>
    <description>Adverse events (local and/or systemic) contributable to Iscador® Qu</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with unexpected adverse events (UAE) contributed to conventional oncological therapy (radio-, chemo-, targeted therapy).</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Test group with Iscador® Qu</arm_group_label>
    <description>The test group will receive the mistletoe extract Iscador® Qu as supportive treatment in addition to post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>The parallel control group will receive no mistletoe but only post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patients visiting the center with colorectal cancer stage UICC II-IV and meeting the
        eligibility criteria will be asked to participate.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of colorectal cancer, UICC stage II-IV

          -  Age between 18 (Austria: 19) and 85 years

          -  No previous malign tumor

          -  Surgical resection of the tumor if indicated

          -  (Post-operative) conventional oncological therapy and measurements, or passive
             after-care (&quot;best care&quot;)

          -  Follow-up for several years feasible

          -  Patient gives written consent to use the anonymized date for evaluation

        Exclusion Criteria:

          -  Anal cancer

          -  Other Iscador® sorts than Qu in the test group

          -  Other mistletoe preparations in the test group

          -  Any mistletoe preparation in the control group

          -  Non-oncological immunomodulating, -stimulating or -suppressive drugs (e.g. Echinacea,
             interferons, Polyerga®, BCG, azathioprine). Allowed are approved tumor inhibiting
             immuno- or targeted therapies (e.g. bevacizumab, cetuximab) and tumor specific
             vaccines

          -  HIV infection, Aids, organ transplantation

          -  High-dose systemic glucocorticoids

          -  Contraindications for Iscador® Qu (allergy against mistletoe, acute inflammatory
             disease or fever &gt; 38.5°C, active tuberculosis, hyperthyreosis with not-adjusted
             metabolism, primary brain or spinal tumor, brain metastases)

          -  Known mistletoe intolerance

          -  Patients participating in another clinical study with non-approved substances
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Seufferlein, Prof. M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinic Halle (Saale)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerhard M Stauder, PhD</last_name>
    <phone>+49 (8171) 96269</phone>
    <email>stauder@ifag.biz</email>
  </overall_contact>
  <location>
    <facility>
      <name>5th Med., Clinic Hietzing</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Stein, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leo Auerbach, Prof. MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Augusta Clinic</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Behringer, Prof. MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ Fulda</name>
      <address>
        <city>Fulda</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Distelrath, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinic - Internal Medicine I</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Seufferlein, Prof. M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Thomas Seufferlein, Prof. M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Herdecke, private University</name>
      <address>
        <city>Herdecke</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Glaser, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Med. Clinic III, University Munich, Grosshadern</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Heinemann, Prof. MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinic Kloster Paradiese</name>
      <address>
        <city>Soest</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eckhard Böcher, Prof. MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Med 1, University Clinic Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Götz PL von Wichert, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Ostermann T, Raak C, Büssing A. Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review. BMC Cancer. 2009 Dec 18;9:451. doi: 10.1186/1471-2407-9-451.</citation>
    <PMID>20021637</PMID>
  </reference>
  <reference>
    <citation>Friedel WE, Matthes H, Bock PR, Zänker KS. Systematic evaluation of the clinical effects of supportive mistletoe treatment within chemo- and/or radiotherapy protocols and long-term mistletoe application in nonmetastatic colorectal carcinoma: multicenter, controlled, observational cohort study. J Soc Integr Oncol. 2009 Fall;7(4):137-45.</citation>
    <PMID>19883529</PMID>
  </reference>
  <reference>
    <citation>Ziegler R. Mistletoe Preparation Iscador: Are there Methodological Concerns with Respect to Controlled Clinical Trials? Evid Based Complement Alternat Med. 2009 Mar;6(1):19-30. doi: 10.1093/ecam/nem121. Epub 2007 Oct 4.</citation>
    <PMID>18955241</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2011</study_first_submitted>
  <study_first_submitted_qc>October 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2011</study_first_posted>
  <last_update_submitted>July 1, 2013</last_update_submitted>
  <last_update_submitted_qc>July 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>mistletoe</keyword>
  <keyword>supportive treatment</keyword>
  <keyword>long-term study</keyword>
  <keyword>non-interventional cohort study</keyword>
  <keyword>controlled study with parallel groups</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Viscum album peptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

